Xenetic Biosciences Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (NASDAQ: XBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.27%. A quarter ago, it was expected that this company would post a loss of $0.87 per share when it actually produced a loss of $0.77, delivering a surprise of 11.49%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Xenetic Biosciences, which belongs to the Zacks Medical – Drugs industry, posted revenues of $0.51 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 21.39%. This compares to year-ago revenues of $0.61 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings …
Full story available on Benzinga.com